Review of Current Understanding of Pituitary Pars Intermedia Dysfunction

Total Page:16

File Type:pdf, Size:1020Kb

Review of Current Understanding of Pituitary Pars Intermedia Dysfunction IN-DEPTH: GERIATRIC MEDICINE/METABOLICS Review of Current Understanding of Pituitary Pars Intermedia Dysfunction Dianne McFarlane, DVM, PhD, Diplomate ACVIM Equine pituitary pars intermedia dysfunction (PPID) is a commonly diagnosed disease in the aged equine population. Recognition of PPID has increased considerably over the past two decades, in part because of an increase in client awareness of the condition as well as an increase in the number of aged horses receiving veterinary equine PPID care. This review focuses on the most current understanding of the development and progression of equine PPID. Author’s address: Oklahoma State University, Department of Physiological Sciences, Center of Veterinary Health Sciences, Still- water, OK 74078; e-mail: [email protected]. © 2013 AAEP. 1. Introduction is produced in the pars intermedia of the healthy horse.1 Anatomy and Function of the Equine Pituitary Equine pars intermedia activity has been shown The equine pituitary gland lies ventral to the optic to be inhibited by dopamine and stimulated by chiasm, separated from the brain by a fold of dura thyrotopin-releasing hormone.2,3 The pars inter- mater known as the diaphragma sellae. It is sus- media receives direct innervation from the dopami- pended from the hypothalamus by the infundibular nergic neurons of the periventricular nucleus of stalk. The equine pituitary gland has four lobes; the hypothalamus. These axons project through the pars distalis, pars intermedia, pars tuberalis the infundibular stalk along the periphery of the (collectively known as the adenohypophysis), and pars nervosa, then travel into the pars intermedia, pars nervosa (neurohypophysis). where they terminate on the endocrine cells of the Melanotropes of the pars intermedia produce a pars intermedia, the melanotropes. Dopamine is hormone precursor protein, pro-opiomelancortin released at the pars intermedia from the nerve ter- (POMC), which undergoes extensive tissue-specific minals of the hypothalamic periventricular neurons cleavage to yield adrenocorticotropic hormone (ACTH), that synapse directly on the melanotropes.4 In the melanocyte-stimulating hormones (MSH), ␤-endor- presence of dopamine secretion of pars intermedia, phin, corticotrophin-like intermediate lope peptide POMC-derived peptide hormones are decreased. (CLIP), lipotropins, and several other small pep- If dopamine is removed either by surgically cutting tides. In the pars intermedia of the healthy ani- the hypothalamic pituitary connection or by geneti- mal, the primary hormones produced are ␣-MSH, cally deleting the dopamine receptor, melanotropes ␤-endorphin, and CLIP. Nearly all plasma ACTH will proliferate, hypertrophy, and increase produc- originates from the pars distalis, and minimal ACTH tion of POMC-derived peptides.5–7 NOTES 294 2013 ր Vol. 59 ր AAEP PROCEEDINGS IN-DEPTH: GERIATRIC MEDICINE/METABOLICS The products of POMC are diverse and highly curs to the dopaminergic neurons, although at this pleiotrophic in function. ␣-MSH has a role in metab- time it is unknown whether oxidative stress is a olism, obesity, stress, and inflammation. Because of cause or consequence of PPID.25–27 these critical functions, this hormone is currently the Neuronal accumulation and aggregation of mis- focus of significant research attention, with more than folded proteins is a mechanism that contributes 1250 PubMed citations in the past 5 years alone. to the pathogenesis of most neurodegenerative dis- ␣-MSH induces an anorexic response and feeling of eases, including Parkinson’s disease, a dopamin- satiety8 and has broad anti-inflammatory effects that ergic neurodegenerative disease of aged people. include decreased production of a wide array of cyto- In Parkinson disease, the protein that accumulates kines and other molecules, factors that contribute in the dopaminergic neurons is ␣-synuclein. ␣- to inflammation.9,10 ␣-MSH also impairs neutro- Synuclein is natively unfolded; however, under cer- phil function, including oxidative burst, chemotaxis, tain cellular conditions, ␣-synuclein can aggregate and adhesion.11,12 CLIP is the cleavage product in dopaminergic nerve terminals, disrupting cellular generated from the c-terminal portion of ACTH. function and triggering cell death.28 Conditions Little is known about the function of CLIP; how- that promote accumulation of ␣-synuclein include ever, both CLIP and its cleavage product, ␤-cell excessive concentration caused by increased produc- tropin, have been shown to stimulate the release of tion or decreased clearance, oxidation or nitration, insulin from rodent beta cells.13 ␤-Endorphin is a and synuclein gene mutations.29,30 ␣-Synuclein potent endogenous opioid ␮-receptor agonist that protein and gene expression was found to be in- functions in analgesia and reduction of pain- creased in the pars intermedia of horses with associated inflammation. PPID.21 In addition to being more abundant, pars Similar to several other species such as hamsters intermedia ␣-synuclein appears to be excessively and sheep, activity of the pars intermedia in horses nitrated in horses with PPID, a modification that has a robust seasonal rhythm, with increased output promotes aggregation.21 It is unknown if failure occurring as day length shortens.14–19 As a result, of protein clearance also contributes to ␣-synuclein the plasma concentration of the pars intermedia accumulation in horses with PPID. Misfolded pro- hormones, including ␣-MSH, are greater in the au- teins are removed primarily through autophagy, tumn (August through October) than in the winter the process by which damaged proteins or organelles or spring.18,19 It has been suggested that this ad- are recycled by the lysosome.31 Assessment of au- aptation helps to prepare the animal for the meta- tophagy in the periventricular neurons of horses bolic and nutritional pressures of the approaching with PPID is ongoing. winter. 3. Clinical Signs of PPID and Diagnostic Testing 2. Pituitary Pars Intermedia Dysfunction Clinical signs of PPID probably are the result of Equine PPID is associated with increased size and overexpression of the pars intermedia hormones. activity of the pars intermedia. At necropsy, horses Late in the disease, it is also possible that loss of with PPID have enlarged pituitary glands caused hormones from the adjacent, compressed lobes of the by hyperplasia, hypertrophy, and a single large or pituitary may also contribute to the clinical syn- multiple small adenomas. Enlargement of the pars drome. Weight loss caused by muscle atrophy, be- intermedia is often accompanied by compression of havioral changes, secondary infections, and changes adjacent structures. PPID was previously charac- in haircoat are some of the most common signs of terized as a benign neoplasia of the equine pituitary PPID. Laminitis occurs with PPID but less fre- gland; however, clinical, pharmacological, biochem- quently than was originally suggested. It is likely ical, and histological data all indicate that PPID is that laminitis occurs only in horses with PPID and a neurodegenerative disease with loss of inhibitory concurrent insulin dysregulation. Further work is dopaminergic input to the pars intermedia. Typi- ongoing to identify the mechanism of development of cal of any neurodegenerative disease, age is the endocrinopathic lamintis. primary risk factor for PPID, and progression of Testing for PPID involves measurement of en- clinical signs occur slowly, making early diagnosis dogenous hormone concentrations, including ACTH problematic. or ␣-MSH or dynamic testing. Dynamic testing, In horses with PPID, there is a marked reduc- which measures the response of the pars intermedia tion of dopamine in pars intermedia tissue20 as well to stimulation or inhibition, may be a more discrim- as a profound loss of dopaminergic periventricular inating approach to disease diagnosis. Because of nerve terminals and cell bodies.21 Further evi- the increase in PI activity in the fall, false-positive dence that PPID results from loss of dopamine is the diagnostic test results for PPID are common when improvement in clinical signs and plasma hormone testing is performed during the autumn if refer- concentration that is observed when horses with ence intervals are not adjusted for season.18–20 PPID are treated with a dopamine agonist such as In addition, clinical signs of PPID are often more pergolide.22–24 Although the precise cause of neu- pronounced in the autumn, most notably an in- rodegeneration in PPID is unknown, several studies creased incidence of laminitis.32 Because pasture have provided evidence that oxidative damage oc- composition also changes significantly with season, AAEP PROCEEDINGS ր Vol. 59 ր 2013 295 IN-DEPTH: GERIATRIC MEDICINE/METABOLICS studies are needed to determine the role of hormone weight, and metabolic hormones in rams. Am J Physiol increase in seasonal development of laminitis.33 Regul Integr Comp Physiol 2001;281:R76–R90. 17. Lincoln GA, Richardson M. Photo-neuroendocrine control of Diagnostic testing for PPID will be discussed in more seasonal cycles in body weight, pelage growth and reproduc- detail in another session. tion: lessons from the HPD sheep model. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998;119:283–294. 18. McFarlane D, Donaldson MT, McDonnell SM, et al. Effects References of season and sample handling on measurement of plasma 1. Wilson MG, Nicholson WE, Holscher MA, et al. Proopioli- alpha-melanocyte-stimulating hormone concentrations in pomelanocortin peptides in normal pituitary,
Recommended publications
  • Leptin Stimulates Pituitary Prolactin Release Through an Extracellular Signal-Regulated Kinase-Dependent Pathway
    275 Leptin stimulates pituitary prolactin release through an extracellular signal-regulated kinase-dependent pathway Christian K Tipsmark, Christina N Strom, Sean T Bailey and Russell J Borski Department of Zoology, North Carolina State University, Raleigh, North Carolina 27695-7617, USA (Correspondence should be addressed to C K Tipsmark who is now at Institute of Biology, University of Southern Denmark, Campusvej 55, DK-5230 Odense M, Denmark; Email: [email protected]) Abstract Leptin was initially identified as a regulator of appetite and leptin are mediated by the activation of extracellular signal- weight control centers in the hypothalamus, but appears to be regulated kinase (ERK1/2) but nothing is known about the involved in a number of physiological processes. This study cellular mechanisms by which leptin might regulate PRL was carried out to examine the possible role of leptin in secretion in vertebrates. We therefore tested whether regulating prolactin (PRL) release using the teleost pituitary ERK1/2 might be involved in the leptin PRL response and model system. This advantageous system allows isolation of a found that the ERK inhibitor, PD98059, hindered leptin- nearly pure population of lactotropes in their natural, in situ induced PRL release. We further analyzed leptin response by aggregated state. The rostral pars distalis were dissected from quantifying tyrosine and threonine phosphorylation of tilapia pituitaries and exposed to varying concentrations of ERK1/2 using western blots. One hour incubation with leptin (0, 1, 10, 100 nM) for 1 h. Release of PRL was leptin induced a concentration-dependent increase in stimulated by leptin in a potent and concentration-dependent phosphorylated, and thus active, ERK1/2.
    [Show full text]
  • A Comparative Survey of the RF-Amide Peptide Superfamily
    EDITORIAL published: 10 August 2015 doi: 10.3389/fendo.2015.00120 Editorial: A comparative survey of the RF-amide peptide superfamily Karine Rousseau 1*, Sylvie Dufour 1 and Hubert Vaudry 2 1 Laboratory of Biology of Aquatic Organisms and Ecosystems (BOREA), Muséum National d’Histoire Naturelle, CNRS 7208, IRD 207, Université Pierre and Marie Curie, UCBN, Paris, France, 2 Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, INSERM U982, International Associated Laboratory Samuel de Champlain, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Mont-Saint-Aignan, France Keywords: RF-amide peptides, receptors, evolution, functions, deuterostomes, protostomes The first member of the RF-amide peptide superfamily to be characterized, in 1977, was the cardioexcitatory peptide, FMRFamide, isolated from the ganglia of the clam Macrocallista nimbosa (1). Since then, a large number of such peptides, designated after their C-terminal arginine (R) and amidated phenylalanine (F) residues, have been identified in representative species of all major phyla. The discovery, 12 years ago, that the RF-amide peptide kisspeptin, acting via GPR54, was essential for the onset of puberty and reproduction, has been a major breakthrough in reproductive physiology (2–4). It has also put in front of the spotlights RF-amide peptides and has invigo- rated research on this superfamily of regulatory neuropeptides. The present Research Topic aims at illustrating major advances achieved, through comparative studies in (mammalian and non- mammalian) vertebrates and invertebrates, in the knowledge of RF-amide peptides in terms of evolutionary history and physiological significance. Since 2006, by means of phylogenetic analyses, the superfamily of RFamide peptides has been divided into five families/groups in vertebrates (5, 6): kisspeptin, 26RFa/QRFP, GnIH (including LPXRFa and RFRP), NPFF, and PrRP.
    [Show full text]
  • CCK-8S) of Protein Phosphorylation in the Neostriatum (Forskonln/N-Methyl-D-Aspartic Acid/Glutamate) GRETCHEN L
    Proc. Natl. Acad. Sci. USA Vol. 90, pp. 11277-11281, December 1993 Neurobiology Regulation by the neuropeptide cholecystokinin (CCK-8S) of protein phosphorylation in the neostriatum (forskonln/N-methyl-D-aspartic acid/glutamate) GRETCHEN L. SNYDER*, GILBERTO FISONE*, PATRIZIA MORINOt, VIDAR GUNDERSEN*, OLE PETTER OTTERSEN*, TOMAS HOKFELTt, AND PAUL GREENGARD*§ *Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, NY 10021; tDepartment of Histology and Neurobiology, Karolinska Institute, S-10401, Stockholm, Sweden; and *Department of Anatomy, University of Oslo, Blindern, N-0317 Oslo, Norway Contributed by Tomas Hokfelt, August 16, 1993 ABSTRACT Despite physiological evidence that cholecys- rons, apparently through a mechanism that involves the tokinin (CCK) is an excitatory neurotransmitter in the brain, release of an excitatory neurotransmitter and activation of little is known about its mechanism of action. CCK immuno- NMDA receptors. reactivity in the brain, including projections to the striatum, is primarily attributable to the sulfated octapeptide CCK-8S. We report here that CCK-8S abolishes cAMP-dependent phos- MATERIALS AND METHODS phorylation ofa dopamine- and cAMP-regulated 32-kDa phos- Materials. RPMI 1640 balanced salt solution, bovine serum phoprotein (DARPP-32) in striatal neurons. The effect of albumin, and 3-isobutylmethylxanthine were obtained from CCK-8S is prevented by antagonists of CCKB and N-methyl- Sigma; forskolin was from Calbiochem; NMDA and (+)-MK- D-aspartate receptors. Our results support a model in which 801 hydrogen maleate (MK-801) were from Research Bio- CCK-8S, originating from CCK or CCK/glutamate cortico- chemicals; CCK-8S was from Bachem; CI-988 was from J. striatal neurons, promotes the release of an excitatory neuro- Hughes; cAMP, RIA, and ECL Western blotting detection transmitter that causes the dephosphorylation and inactivation kits were from Amersham; and goat anti-mouse horseradish of DARPP-32, a potent protein phosphatase inhibitor, thereby peroxidase-linked antibody was from Pierce.
    [Show full text]
  • TRH-Like Peptides
    Physiol. Res. 60: 207-215, 2011 https://doi.org/10.33549/physiolres.932075 REVIEW TRH-Like Peptides R. BÍLEK1, M. BIČÍKOVÁ1, L. ŠAFAŘÍK2 1Institute of Endocrinology, Prague, Czech Republic, 2Urology Clinic, Beroun, Czech Republic Received September 6, 2010 Accepted October 8, 2010 On-line November 29, 2010 Summary of the leaders working in the area concerning the TRH TRH-like peptides are characterized by substitution of basic research was Professor V. Schreiber from Prague, Czech amino acid histidine (related to authentic TRH) with neutral or Republic, which already in 1959 formulated the acidic amino acid, like glutamic acid, phenylalanine, glutamine, hypothesis that adenohypophyseal acid phosphatase is tyrosine, leucin, valin, aspartic acid and asparagine. The related to thyrotropin secretion and that TRH is its presence of extrahypothalamic TRH-like peptides was reported in possible activator (Schreiber and Kmentova 1959, peripheral tissues including gastrointestinal tract, placenta, neural Schreiber et al. 1962). TRH precursor, human prepro- tissues, male reproductive system and certain endocrine tissues. TRH, consists of 242 amino acid residues, and contains Work deals with the biological function of TRH-like peptides in six separate copies of the TRH progenitor sequence different parts of organisms where various mechanisms may (Satoh and Mori 1994), which determine the primary serve for realisation of biological function of TRH-like peptides as structure of TRH as a tripeptide pyroglutamyl-histidinyl- negative feedback to the pituitary exerted by the TRH-like proline amide. The transcriptional unit of prepro-TRH is peptides, the role of pEEPam such as fertilization-promoting localized on chromosome 3 in humans (three exons peptide, the mechanism influencing the proliferative ability of interrupted by two introns) (Yamada et al.
    [Show full text]
  • Peptide Handbook a Guide to Peptide Design and Applications in Biomedical Research
    Peptide Handbook A Guide to Peptide Design and Applications in Biomedical Research First Edition www.GenScript.com GenScript USA Inc. 860 Centennial Ave. Piscataway, NJ 08854 USA Phone: 1-732-885-9188 Toll-Free: 1-877-436-7274 Fax: 1-732-885-5878 Table of Contents The Universe of Peptides Reliable Synthesis of High-Quality Peptides Molecular structure 3 by GenScript Characteristics 5 Categories and biological functions 8 Analytical methods 10 Application of Peptides Research in structural biology 12 Research in disease pathogenesis 12 Generating antibodies 13 FlexPeptideTM Peptide Synthesis Platform which takes advantage of the latest Vaccine development 14 peptide synthesis technologies generates a large capacity for the quick Drug discovery and development 15 synthesis of high-quality peptides in a variety of lengths, quantities, purities Immunotherapy 17 and modifications. Cell penetration-based applications 18 Anti-microorganisms applications 19 Total Quality Management System based on multiple rounds of MS and HPLC Tissue engineering and regenerative medicine 20 analyses during and after peptide synthesis ensures the synthesis of Cosmetics 21 high-quality peptides free of contaminants, and provides reports on peptide Food industry 21 solubility, quality and content. Synthesis of Peptides Diverse Delivery Options help customers plan their peptide-based research Chemical synthesis 23 according to their time schedule and with peace of mind. Microwave-assisted technology 24 ArgonShield™ Packing eliminates the experimental variation caused by Ligation technology 26 oxidization and deliquescence of custom peptides through an innovative Recombinant technology 28 Modifications packing and delivery technology. 28 Purification 30 Expert Support offered by Ph.D.-level scientists guides customers from Product identity and quality control 31 peptide design and synthesis to reconstitution and application.
    [Show full text]
  • Effect of the Natural Sweetener Xylitol on Gut Hormone Secretion and Gastric Emptying in Humans: a Pilot Dose-Ranging Study
    nutrients Article Effect of the Natural Sweetener Xylitol on Gut Hormone Secretion and Gastric Emptying in Humans: A Pilot Dose-Ranging Study Anne Christin Meyer-Gerspach 1,2,* , Jürgen Drewe 3, Wout Verbeure 4 , Carel W. le Roux 5, Ludmilla Dellatorre-Teixeira 5, Jens F. Rehfeld 6, Jens J. Holst 7 , Bolette Hartmann 7, Jan Tack 4, Ralph Peterli 8, Christoph Beglinger 1,2 and Bettina K. Wölnerhanssen 1,2,* 1 St. Clara Research Ltd. at St. Claraspital, 4002 Basel, Switzerland; [email protected] 2 Faculty of Medicine, University of Basel, 4001 Basel, Switzerland 3 Department of Clinical Pharmacology and Toxicology, University Hospital of Basel, 4001 Basel, Switzerland; [email protected] 4 Translational Research Center for Gastrointestinal Disorders, Catholic University of Leuven, 3000 Leuven, Belgium; [email protected] (W.V.); [email protected] (J.T.) 5 Diabetes Complications Research Centre, Conway Institute University College Dublin, 3444 Dublin, Ireland; [email protected] (C.W.l.R.); [email protected] (L.D.-T.) 6 Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark; [email protected] 7 Department of Biomedical Sciences and Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark; [email protected] (J.J.H.); [email protected] (B.H.) 8 Department of Surgery, Clarunis, St. Claraspital, 4002 Basel, Switzerland; [email protected] * Correspondence: [email protected] (A.C.M.-G.); [email protected] (B.K.W.); Tel.: +41-61-685-85-85 (A.C.M.-G.
    [Show full text]
  • What Is Pancreatic Polypeptide and What Does It Do?
    What is Pancreatic Polypeptide and what does it do? This document aims to evaluate current understanding of pancreatic polypeptide (PP), a gut hormone with several functions contributing towards the maintenance of energy balance. Successful regulation of energy homeostasis requires sophisticated bidirectional communication between the gastrointestinal tract and central nervous system (CNS; Williams et al. 2000). The coordinated release of numerous gastrointestinal hormones promotes optimal digestion and nutrient absorption (Chaudhri et al., 2008) whilst modulating appetite, meal termination, energy expenditure and metabolism (Suzuki, Jayasena & Bloom, 2011). The Discovery of a Peptide Kimmel et al. (1968) discovered PP whilst purifying insulin from chicken pancreas (Adrian et al., 1976). Subsequent to extraction of avian pancreatic polypeptide (aPP), mammalian homologues bovine (bPP), porcine (pPP), ovine (oPP) and human (hPP), were isolated by Lin and Chance (Kimmel, Hayden & Pollock, 1975). Following extensive observation, various features of this novel peptide witnessed its eventual classification as a hormone (Schwartz, 1983). Molecular Structure PP is a member of the NPY family including neuropeptide Y (NPY) and peptide YY (PYY; Holzer, Reichmann & Farzi, 2012). These biologically active peptides are characterized by a single chain of 36-amino acids and exhibit the same ‘PP-fold’ structure; a hair-pin U-shaped molecule (Suzuki et al., 2011). PP has a molecular weight of 4,240 Da and an isoelectric point between pH6 and 7 (Kimmel et al., 1975), thus carries no electrical charge at neutral pH. Synthesis Like many peptide hormones, PP is derived from a larger precursor of 10,432 Da (Leiter, Keutmann & Goodman, 1984). Isolation of a cDNA construct, synthesized from hPP mRNA, proposed that this precursor, pre-propancreatic polypeptide, comprised 95 residues (Boel et al., 1984) and is processed to produce three products (Leiter et al., 1985); PP, an icosapeptide containing 20-amino acids and a signal peptide (Boel et al., 1984).
    [Show full text]
  • Chronic Iodine Deficiency As Cause of Neoplasia in Thyroid and Pituitary of Aged Rats
    203 CHRONIC IODINE DEFICIENCY AS CAUSE OF NEOPLASIA IN THYROID AND PITUITARY OF AGED RATS. F. BIELSCHOWSKY. From the, Hugh Adam Cancer Research Department of the Medical School and the New Zealand Branch of the British Empire Cancer Campaign, University of Otago, Dunedin. Received for publication April 7, 1953. JUDGING from the literature, adenomata occur more frequently in the pitu- itaries than in the thyroids of aged rats. At the routine autopsies of 154 albinos of the Wistar strain, 41 of which were males, 86 intact and 27 spayed females, 24 cases of adenoma of the pituitary were discovered. Seven of these occurred in the males, 16 in the intact females and only one in an ovariectomised animal. The average age of these rats was 2 years. Adenomata of the thyroid were found in 5 animals, 4 times in combination with neoplastic lesions of the pituitary. Post-mortem examinations performed on old rats of a more recently acquired hooded strain have furnished three additional cases of tumours of thyroid and pituitary. The paper describes the findings in these 8 rats, and endeavours to interpret the pathogenesis of the neoplastic lesions found in the two endocrine glands as a sequel to chronic iodine deficiency. MATERIALr AND METHODS. Like all our stock rats, the animals described in this paper were kept during their lifetime in a room separated from the experimental animals and had there- fore no contact with goitrogenic or carcinogenic agents. The diet consisted of a dry mixture of bran 30 per cent, pollard 35 per cent, meat meal 15 per cent, maize meal 15 per cent and bone flour 5 per cent, supplemented by wheat and kibbled maize, and once weekly by green vegetables and cod liver oil.
    [Show full text]
  • Rfamide Peptides: Structure, Function, Mechanisms and Pharmaceutical Potential
    Pharmaceuticals 2011, 4, 1248-1280; doi:10.3390/ph4091248 OPEN ACCESS Pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review RFamide Peptides: Structure, Function, Mechanisms and Pharmaceutical Potential Maria Findeisen †, Daniel Rathmann † and Annette G. Beck-Sickinger * Institute of Biochemistry, Leipzig University, Brüderstraße 34, 04103 Leipzig, Germany; E-Mails: [email protected] (M.F.); [email protected] (D.R.) † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +49-341-9736900; Fax: +49-341-9736909. Received: 29 August 2011; in revised form: 9 September 2011 / Accepted: 15 September 2011 / Published: 21 September 2011 Abstract: Different neuropeptides, all containing a common carboxy-terminal RFamide sequence, have been characterized as ligands of the RFamide peptide receptor family. Currently, five subgroups have been characterized with respect to their N-terminal sequence and hence cover a wide pattern of biological functions, like important neuroendocrine, behavioral, sensory and automatic functions. The RFamide peptide receptor family represents a multiligand/multireceptor system, as many ligands are recognized by several GPCR subtypes within one family. Multireceptor systems are often susceptible to cross-reactions, as their numerous ligands are frequently closely related. In this review we focus on recent results in the field of structure-activity studies as well as mutational exploration of crucial positions within this GPCR system. The review summarizes the reported peptide analogs and recently developed small molecule ligands (agonists and antagonists) to highlight the current understanding of the pharmacophoric elements, required for affinity and activity at the receptor family.
    [Show full text]
  • Co-Regulation of Hormone Receptors, Neuropeptides, and Steroidogenic Enzymes 2 Across the Vertebrate Social Behavior Network 3 4 Brent M
    bioRxiv preprint doi: https://doi.org/10.1101/435024; this version posted October 4, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Co-regulation of hormone receptors, neuropeptides, and steroidogenic enzymes 2 across the vertebrate social behavior network 3 4 Brent M. Horton1, T. Brandt Ryder2, Ignacio T. Moore3, Christopher N. 5 Balakrishnan4,* 6 1Millersville University, Department of Biology 7 2Smithsonian Conservation Biology Institute, Migratory Bird Center 8 3Virginia Tech, Department of Biological Sciences 9 4East Carolina University, Department of Biology 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 bioRxiv preprint doi: https://doi.org/10.1101/435024; this version posted October 4, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Running Title: Gene expression in the social behavior network 2 Keywords: dominance, systems biology, songbird, territoriality, genome 3 Corresponding Author: 4 Christopher Balakrishnan 5 East Carolina University 6 Department of Biology 7 Howell Science Complex 8 Greenville, NC, USA 27858 9 [email protected] 10 2 bioRxiv preprint doi: https://doi.org/10.1101/435024; this version posted October 4, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions
    Molecular Pharmacology Fast Forward. Published on June 2, 2020 as DOI: 10.1124/mol.120.119388 This article has not been copyedited and formatted. The final version may differ from this version. File name: Opioid peptides v45 Date: 5/28/20 Review for Mol Pharm Special Issue celebrating 50 years of INRC Five decades of research on opioid peptides: Current knowledge and unanswered questions Lloyd D. Fricker1, Elyssa B. Margolis2, Ivone Gomes3, Lakshmi A. Devi3 1Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; E-mail: [email protected] 2Department of Neurology, UCSF Weill Institute for Neurosciences, 675 Nelson Rising Lane, San Francisco, CA 94143, USA; E-mail: [email protected] 3Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, Annenberg Downloaded from Building, One Gustave L. Levy Place, New York, NY 10029, USA; E-mail: [email protected] Running Title: Opioid peptides molpharm.aspetjournals.org Contact info for corresponding author(s): Lloyd Fricker, Ph.D. Department of Molecular Pharmacology Albert Einstein College of Medicine 1300 Morris Park Ave Bronx, NY 10461 Office: 718-430-4225 FAX: 718-430-8922 at ASPET Journals on October 1, 2021 Email: [email protected] Footnotes: The writing of the manuscript was funded in part by NIH grants DA008863 and NS026880 (to LAD) and AA026609 (to EBM). List of nonstandard abbreviations: ACTH Adrenocorticotrophic hormone AgRP Agouti-related peptide (AgRP) α-MSH Alpha-melanocyte stimulating hormone CART Cocaine- and amphetamine-regulated transcript CLIP Corticotropin-like intermediate lobe peptide DAMGO D-Ala2, N-MePhe4, Gly-ol]-enkephalin DOR Delta opioid receptor DPDPE [D-Pen2,D- Pen5]-enkephalin KOR Kappa opioid receptor MOR Mu opioid receptor PDYN Prodynorphin PENK Proenkephalin PET Positron-emission tomography PNOC Pronociceptin POMC Proopiomelanocortin 1 Molecular Pharmacology Fast Forward.
    [Show full text]
  • The Role of Corticotropin-Releasing Hormone at Peripheral Nociceptors: Implications for Pain Modulation
    biomedicines Review The Role of Corticotropin-Releasing Hormone at Peripheral Nociceptors: Implications for Pain Modulation Haiyan Zheng 1, Ji Yeon Lim 1, Jae Young Seong 1 and Sun Wook Hwang 1,2,* 1 Department of Biomedical Sciences, College of Medicine, Korea University, Seoul 02841, Korea; [email protected] (H.Z.); [email protected] (J.Y.L.); [email protected] (J.Y.S.) 2 Department of Physiology, College of Medicine, Korea University, Seoul 02841, Korea * Correspondence: [email protected]; Tel.: +82-2-2286-1204; Fax: +82-2-925-5492 Received: 12 November 2020; Accepted: 15 December 2020; Published: 17 December 2020 Abstract: Peripheral nociceptors and their synaptic partners utilize neuropeptides for signal transmission. Such communication tunes the excitatory and inhibitory function of nociceptor-based circuits, eventually contributing to pain modulation. Corticotropin-releasing hormone (CRH) is the initiator hormone for the conventional hypothalamic-pituitary-adrenal axis, preparing our body for stress insults. Although knowledge of the expression and functional profiles of CRH and its receptors and the outcomes of their interactions has been actively accumulating for many brain regions, those for nociceptors are still under gradual investigation. Currently, based on the evidence of their expressions in nociceptors and their neighboring components, several hypotheses for possible pain modulations are emerging. Here we overview the historical attention to CRH and its receptors on the peripheral nociception and the recent increases in information regarding their roles in tuning pain signals. We also briefly contemplate the possibility that the stress-response paradigm can be locally intrapolated into intercellular communication that is driven by nociceptor neurons.
    [Show full text]